Yes. The FDA has issued guidance recommending that bubble bath products marketed for children carry cautionary statements about limiting exposure time and rinsing thoroughly, due to the potential for urinary tract irritation from prolonged contact with surfactants. Importers of child-directed bath preparations should review current FDA guidance and ensure compliant labeling before distribution. Consulting a licensed customs broker or regulatory specialist is advisable.

Effervescent bath tablets are classified as cosmetics if their claims are limited to cleansing, moisturizing, or fragrance. If the product claims therapeutic benefits — such as relieving muscle pain or treating a skin condition — it may be reclassified as a drug or medical device, triggering a separate FDA review pathway. Importers should audit all label claims, including digital marketing materials, to ensure they remain within cosmetic scope.